I've put nothing forward but fact, only to have IMU flogs tell me I'm missing something.
The PD1-Vaxx + atezolizumab trial has seen the combination dosed in 10 patients out of a planned ~48. You wouldn't terminate this trial and indicate you're looking to offload this platform if the results had been at all positive.
As I've said previously; IMU will have canned this study to reduce the liabilities ($$$) on the B Cell platform so that it looks more enticing to an acquirer. Suspect the B Cell platform is flogged off for cents on the dollar, if they can find a buyer.
IMU Price at posting:
3.8¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)